Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andrea Martin

Physician Assistant Saint Louis, MO Physician Assistant

NPI 1740523885 CMS profile 11198232

3009 N Ballas Rd, Ste 100B, Saint Louis, MO 63131

Open in the dashboard

General payments

$16,852

1,011 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrea Martin of Saint Louis, MO is reported in the CMS Open Payments database as having received $16,852 across 1,011 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,880 168
2024 General $3,865 207
2023 General $3,430 214
2022 General $3,521 223
2021 General $3,156 199

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrea Martin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Andrea Martin were reported at $2,880. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Andrea Martin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,156 $132 $37–$438 $132
2022 $3,521 $155 $48–$522 $149
2023 $3,430 $167 $52–$557 $160
2024 $3,865 $178 $55–$600 $164
2025 $2,880 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,901 166 payments
  2. Novo Nordisk Inc $1,612 79 payments
  3. Lilly USA, LLC $1,106 55 payments
  4. Antares Pharma, Inc. $792 70 payments
  5. UCB, Inc. $710 16 payments
  6. Amgen Inc. $557 37 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $520 35 payments
  8. Tris Pharma Inc $456 50 payments
  9. Axsome Therapeutics, Inc. $447 28 payments
  10. Neos Therapeutics, LP $442 30 payments
  11. Other $7,309 445 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,838 1,008 payments
  2. Education $14 3 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $1,378 79 payments
  2. Bimzelx $710 16 payments
  3. QULIPTA $691 45 payments
  4. RYBELSUS $691 43 payments
  5. VRAYLAR $608 36 payments
  6. XYOSTED $606 47 payments
  7. Wegovy $589 22 payments
  8. ZEPBOUND $503 20 payments
  9. NOCDURNA $474 40 payments
  10. Ozempic $464 40 payments
  11. Other $14,004 926 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

222

Median for Physician Assistant: 241

Drug cost

$59,621

Median for Physician Assistant: $4,110

Branded share of claims

55.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 54 $56,029
Estradiol (Twice Weekly) Estradiol Brand 19 $992
Progesterone Progesterone, Micronized Brand 25 $941
Testosterone Cypionate Generic 13 $559
Glimepiride Generic 13 $273
Trazodone Hcl Generic 24 $180
Spironolactone Generic 13 $147
Vitamin D2 Ergocalciferol (Vitamin D2) Brand 14 $145
Rosuvastatin Calcium Generic 21 $145
Levothyroxine Sodium Generic 15 $106

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
$393 — —
Bimzelx
$326 — —
VRAYLAR
$273 — —
LEQVIO
$226 — —
Dyanavel XR
$208 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

1,011 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record